Trans-catheter aortic valve implantation (TAVI) is by now considered the treatment of choice in patients with severe and symptomatic aortic stenosis deemed at prohibitive or high surgical risk. However, recent evidence has led to broaden TAVI indication to intermediate and low-risk patients [1]. This implies better technologies and minimizing acute complications such as pacemaker implantation, vascular injury, renal failure and radiological exposure [1,2].
